ペット用がん治療薬の市場規模、シェア、成長分析、生物種別、治療法別、投与経路別、がんタイプ別、地域別 - 産業予測、2025-2032年

ペット用がん治療薬市場規模は2023年に4億200万米ドルとなり、2024年の4億4,140万米ドルから2032年には9億3,250万米ドルに成長し、予測期間（2025-2032年）のCAGRは9.8%で推移する見通しです。

世界のペット用がん治療薬市場は、毛皮で覆われた仲間の健康に関するペットオーナーの意識の高まりにより、大きな成長を遂げています。このような動物福祉を優先するシフトは、効果的ながん治療オプションに対する需要の増加に拍車をかけています。これを受けて、業界各社はペット用に特化した新しい治療薬を開発し、がんの診断に直面しているペットの治療成績と生活の質全体の向上を目指しています。さらに、獣医腫瘍学の進歩により、ペットのがんに対する理解が深まり、標的療法の創出につながりつつあります。この進化する市場環境は、動物への思いやりと最先端の科学の進歩が将来有望に交差し、最終的には癌と闘うペットの専門的な医療ニーズに対応することを反映しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制分析

ペット用がん治療薬市場規模：種別

• 市場概要
• 犬
• 猫
• その他の種類

ペット用がん治療薬市場規模セラピー

• 市場概要
• 化学療法
• 免疫療法
• 標的療法
• 併用療法

ペット用がん治療薬市場規模：投与経路別

• 市場概要
• 経口
• 注射

ペット用がん治療薬市場規模：がんの種類別

• 市場概要
• リンパ腫
• 肥満細胞がん
• 悪性黒色腫
• 乳腺がんおよび扁平上皮がん
• その他のがん種

ペット用がん治療薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Elanco Animal Health（US）
• Anivive Lifesciences（US）
• Regeneus（Australia）
• Qbiotics（Australia）
• Zoetis（US）
• VetDC（US）
• AB Science（France）
• Vet Cancer Group（US）
• VetriScience（US）
• Vetnostics（Australia）
• Veterinary Cancer Society（US）
• PetCure Oncology（US）
• Oasmia Pharmaceutical（Sweden）

結論と提言

Pet Cancer Therapeutics Market size was valued at USD 402.0 million in 2023 and is poised to grow from USD 441.4 million in 2024 to USD 932.5 million by 2032, growing at a CAGR of 9.8% during the forecast period (2025-2032).

The global pet cancer therapeutics market is experiencing significant growth due to heightened awareness among pet owners regarding their furry companions' health. This shift towards prioritizing animal welfare has catalyzed an increased demand for effective cancer treatment options. In response, industry players are innovating new therapeutics specifically designed for pets, aiming to enhance treatment outcomes and overall quality of life for those facing cancer diagnoses. Furthermore, advancements in veterinary oncology are deepening the understanding of pet cancer, leading to the creation of targeted therapies. This evolving market landscape reflects a promising intersection of compassion for animals and cutting-edge scientific progress, ultimately addressing the specialized healthcare needs of pets battling cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pet Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pet Cancer Therapeutics Market Segments Analysis

Global Pet Cancer Therapeutics Market is segmented by Species, Therapy, Route of Administration, Cancer Type and region. Based on Species, the market is segmented into Dogs, Cats and Other species. Based on Therapy, the market is segmented into Chemotherapy, Immunotherapy, Targeted therapy and Combination therapy. Based on Route of Administration, the market is segmented into Oral and Injection. Based on Cancer Type, the market is segmented into Lymphoma, Mast cell cancer, Melanoma, Mammary and squamous cell cancer and Other cancer types. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pet Cancer Therapeutics Market

One of the primary drivers propelling the global pet cancer therapeutics market is the growing trend of pet humanization. As pet owners increasingly perceive their pets as cherished family members, there is a heightened readiness to invest in sophisticated healthcare solutions, particularly for cancer treatments. This shift in perspective enhances the demand for effective and compassionate cancer therapies specifically designed for pets, fostering both innovation and expansion within the market. The commitment to providing superior care for beloved animals is fundamentally transforming the landscape of veterinary oncology, leading to advancements and a wider array of therapeutic options.

Restraints in the Pet Cancer Therapeutics Market

A major challenge facing the global pet cancer therapeutics market is the significant financial burden that cancer treatments impose on pet owners. The costs associated with various procedures and medications, including diagnostics, surgeries, radiation therapy, and pharmaceuticals, can be quite high. This economic strain may restrict many pet owners from accessing advanced cancer care options, ultimately forcing them to make tough choices regarding the level of treatment they can provide for their companions. Consequently, despite the growing awareness and demand for effective pet cancer therapeutics, the issue of affordability persists as a vital concern, affecting market dynamics and limiting the availability of these essential treatments.

Market Trends of the Pet Cancer Therapeutics Market

The global pet cancer therapeutics market is witnessing a notable trend centered around personalized treatment strategies. As pet owners and veterinarians increasingly acknowledge the distinct nature of each pet's cancer, there is a growing demand for customized therapeutic solutions, including precision medicine and targeted therapies. Innovations in diagnostics, such as genetic profiling and molecular testing, facilitate more accurate cancer diagnoses, enabling tailored treatment plans that align with the specific tumor characteristics of each pet. This focus on individualized care not only enhances treatment efficacy but also minimizes adverse side effects, reflecting a broader commitment to improving the quality of care and outcomes for pets battling cancer.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Analysis

Global Pet Cancer Therapeutics Market Size by Species & CAGR (2025-2032)

• Market Overview
• Dogs
• Cats
• Other species

Global Pet Cancer Therapeutics Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Combination therapy

Global Pet Cancer Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection

Global Pet Cancer Therapeutics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Lymphoma
• Mast cell cancer
• Melanoma
• Mammary and squamous cell cancer
• Other cancer types

Global Pet Cancer Therapeutics Market Size & CAGR (2025-2032)

• North America (Species, Therapy, Route of Administration, Cancer Type)
  • US
  • Canada
• Europe (Species, Therapy, Route of Administration, Cancer Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Species, Therapy, Route of Administration, Cancer Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Species, Therapy, Route of Administration, Cancer Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Species, Therapy, Route of Administration, Cancer Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Elanco Animal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anivive Lifesciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qbiotics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetDC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vet Cancer Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetriScience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetnostics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veterinary Cancer Society (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oasmia Pharmaceutical (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations